Background: Repository corticotropin injection (RCI) has regulatory approval for many indications, including symptomatic sarcoidosis. This large case series of patients with advanced symptomatic sarcoidosis treated with RCI describes patient characteristics, RCI utilization patterns, concomitant therapies, and physicians' assessments of treatment response.
Methods: Patients ⩾18 years with symptomatic sarcoidosis, treated with RCI in the previous 36 months, who had completed a course of RCI or received RCI for ⩾6 months at the time of data collection were included.
Results: The study included 302 patients (mean age, 51 years; 52%, women) with a mean 4.8 years since initial diagnosis of sarcoidosis. Most patients (76%) had extrapulmonary involvement, primarily in the skin (28%), joints (25%), heart (22%), and eyes (22%); 34% had multiple (⩾2) organ involvement. The mean duration of RCI treatment was 32.5 weeks, with 61.6% of patients continuing RCI therapy for ⩾6 months. The RCI utilization pattern indicated an individualized approach to therapy, with a higher starting dose associated with a shorter duration of therapy compared with a lower starting dose. The percentage of patients who used corticosteroids decreased from 61.3% during the 3 months before initiation of RCI to 12.9% 3 months after RCI therapy; the mean daily dose of corticosteroid decreased from 18.2 mg to 9.9 mg. The proportion of patients given <10 mg/day of prednisone increased from 21% before RCI use to 47% 3 months after RCI use. According to physicians' assessments of change in patients' health status after RCI therapy, overall status improved in 95% of patients, overall symptoms in 73%, lung function in 38%, and inflammation in 33%.
Conclusions: The findings suggest that RCI is a viable treatment option for patients with advanced symptomatic sarcoidosis and provide insights on patient characteristics and practice patterns to help clinicians determine appropriate use.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856972 | PMC |
http://dx.doi.org/10.1177/1753466619888127 | DOI Listing |
Cureus
December 2024
Endocrinology, Mallow General Hospital/University College Cork, Cork, IRL.
Calcium Homeostasis in the human body is regulated by hormones, including parathyroid hormone and vitamin D3. Dysfunction in the form of hypoparathyroidism causes hypocalcaemia. In patients treated for primary hypoparathyroidism with activated vitamin D replacement, iatrogenic hypercalcaemia can occur.
View Article and Find Full Text PDFCureus
October 2024
Internal Medicine, Ascension Saint Joseph Hospital, Chicago, USA.
Sarcoidosis is a granulomatous disease that can affect multiple organs, including the liver. We present a case of a 43-year-old male with hepatic sarcoidosis who presented with jaundice and pruritus. Laboratory findings showed mixed hyperbilirubinemia and elevated liver enzymes.
View Article and Find Full Text PDFNeurohospitalist
September 2024
Department of Neurology, Northwestern Memorial Hospital, Chicago, IL, USA.
Mononeuropathy multiplex is a pattern of progressive sensory and motor deficits in the distribution of two or more peripheral nerves. The differential for mononeuropathy multiplex includes vasculitis, autoimmune disorders, infectious diseases, sarcoidosis, amyloidosis, cryoglobulinemia, and paraneoplastic disease. We present a case of a 42-year-old woman with hypothyroidism who presented with 1 week of ascending numbness and weakness, persistent fevers, and 3 months of constant burning pain in both feet.
View Article and Find Full Text PDFSaudi Med J
October 2024
From the Department of Cardiac Sciences (Alqarawi), College of Medicine, King Saud University, and from the Department of Internal Medicine (Alarifi), King Abdullah University Hospital, Riyadh, Kingdom of Saudi Arabia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!